• Share
  • Email
  • Embed
  • Like
  • Save
  • Private Content
United Kingdom In Vitro Diagnostics Market Outlook to 2018 - Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture
 

United Kingdom In Vitro Diagnostics Market Outlook to 2018 - Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture

on

  • 212 views

 

Statistics

Views

Total Views
212
Views on SlideShare
212
Embed Views
0

Actions

Likes
0
Downloads
1
Comments
0

0 Embeds 0

No embeds

Accessibility

Categories

Upload Details

Uploaded via as Adobe PDF

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

    United Kingdom In Vitro Diagnostics Market Outlook to 2018 - Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture United Kingdom In Vitro Diagnostics Market Outlook to 2018 - Clinical Chemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture Document Transcript

    • United Kingdom In Vitro Diagnostics Market Outlook to 2018 -Clinical Chemistry Genetic Testing, Haematology, Histologyand Cytology, Immuno Chemistry, Infectious Immunology andMicrobiology CultureReport Details:Published:December 2012No. of Pages: 309Price: Single User License – US$2500United Kingdom In Vitro Diagnostics Market Outlook to 2018 - Clinical Chemistry Genetic Testing,Haematology, Histology and Cytology, Immuno Chemistry, Infectious Immunology andMicrobiology CultureSummaryGlobalData’s new report, “United Kingdom In Vitro Diagnostics Market Outlook to 2018 - ClinicalChemistry Genetic Testing, Haematology, Histology and Cytology, Immuno Chemistry, InfectiousImmunology and Microbiology Culture” provides key market data on the United Kingdom In VitroDiagnostics market. The report provides value (USD million), volume (units) and average price(USD) data for each segment and sub-segment within market categories – Immuno Chemistry,Clinical Chemistry, Haematology, Infectious Immunology, Histology And Cytology, MicrobiologyCulture and Genetic Testing. The report also provides company shares and distribution sharesdata for each of the aforementioned market categories. The report is supplemented with globalcorporate-level profiles of the key market participants with information on company financials andpipeline products, wherever available.This report is built using data and information sourced from proprietary databases, primary andsecondary research and in-house analysis by GlobalData’s team of industry experts.Scope- Market size and company share data for In Vitro Diagnostics market categories – ImmunoChemistry, Clinical Chemistry, Haematology, Infectious Immunology, Histology And Cytology,Microbiology Culture and Genetic Testing.- Annualized market revenues (USD million), volume (units) and average price (USD) data for
    • each of the segments and sub-segments within market categories. Data from 2004 to 2011,forecast forward for 7 years to 2018.- 2011 company shares and distribution shares data for each of the market categories.- Global corporate-level profiles of key companies operating within the United Kingdom In VitroDiagnostics market.- Key players covered include Siemens Healthcare, F. Hoffmann-La Roche Ltd., AbbottLaboratories, Beckman Coulter, Inc., Sysmex Corporation, bioMerieux S.A. and others.Reasons to buy- Develop business strategies by identifying the key market categories and segments poised forstrong growth.- Develop market-entry and market expansion strategies.- Design competition strategies by identifying who-stands-where in the United Kingdom In VitroDiagnostics competitive landscape.- Develop capital investment strategies by identifying the key market segments expected toregister strong growth in the near future.- What are the key distribution channels and what’s the most preferred mode of productdistribution – Identify, understand and capitalize.Get your copy of this report @http://www.reportsnreports.com/reports/213266-united-kingdom-in-vitro-diagnostics-market-outlook-to-2018-clinical-chemistry-genetic-testing-haematology-histology-and-cytology-immuno-chemistry-infectious-immunology-and-microbiology-culture.htmlMajor points covered in Table of Contents of this report include1 Table of Contents1 Table of Contents 21.1 List of Tables 71.2 List of Figures 122 Introduction 152.1 What is This Report About? 153 In Vitro Diagnostics In United Kingdom 163.1 In Vitro Diagnostics, Market Segmentation 163.2 In Vitro Diagnostics, United Kingdom, Overall Revenue ($m), USD Constant, 2004-2018 173.3 In Vitro Diagnostics Market, United Kingdom, Revenue Mix ($m), 2011 193.4 In Vitro Diagnostics Market, United Kingdom, Category Contribution (%), 2011 203.5 In Vitro Diagnostics, United Kingdom, Company Share (2010-2011) 274 Clinical Chemistry In United Kingdom 294.1 Clinical Chemistry, Market Segmentation 294.2 Clinical Chemistry Market, United Kingdom, Revenue Mix ($m), 2011 304.3 Clinical Chemistry Market, United Kingdom, Segment Contribution (%), 2011 314.4 Clinical Chemistry Overall Revenue, (2004-2018) 324.5 Clinical Chemistry Distribution Share (2010-2011) 44
    • 4.6 Clinical Chemistry, United Kingdom, Company Share (2010-2011) 455 Genetic Testing In United Kingdom 475.1 Genetic Testing, Market Segmentation 475.2 Genetic Testing Market, United Kingdom, Revenue Mix ($m), 2011 485.3 Genetic Testing Market, United Kingdom, Segment Contribution (%), 2011 495.4 Genetic Testing Overall Revenue, (2004-2018) 505.5 Genetic Testing Distribution Share (2010-2011) 545.6 Genetic Testing, United Kingdom, Company Share (2010-2011) 556 Haematology In United Kingdom 576.1 Haematology Market, Market Segmentation 576.2 Haematology Market, United Kingdom, Revenue Mix ($m), 2011 586.3 Haematology Market, United Kingdom, Segment Contribution (%), 2011 596.4 Haematology Overall Revenue, (2004-2018) 606.5 Haematology Distribution Share (2010-2011) 846.6 Haematology, United Kingdom, Company Share (2010-2011) 857 Histology And Cytology In United Kingdom 877.1 Histology and Cytology Market, Market Segmentation 877.2 Histology And Cytology Market, United Kingdom, Revenue Mix ($m), 2011 887.3 Histology And Cytology Market, United Kingdom, Segment Contribution (%), 2011 897.4 Histology And Cytology Overall Revenue, (2004-2018) 907.5 Histology And Cytology Distribution Share (2010-2011) 947.6 Histology And Cytology, United Kingdom, Company Share (2010-2011) 958 Immuno Chemistry In United Kingdom 978.1 Immuno Chemistry Market, United Kingdom, Revenue Mix ($m), 2011 978.2 Immuno Chemistry Market, United Kingdom, Segment Contribution (%), 2011 988.3 Immuno Chemistry Overall Revenue, (2004-2018) 998.4 Immuno Chemistry Distribution Share (2010-2011) 1278.5 Immuno Chemistry, United Kingdom, Company Share (2010-2011) 1289 Infectious Immunology In United Kingdom 1309.1 Infectious Immunology, Market Segmentation 1309.2 Infectious Immunology Market, United Kingdom, Revenue Mix ($m), 2011 1319.3 Infectious Immunology Market, United Kingdom, Segment Contribution (%), 2011 1329.4 Infectious Immunology Overall Revenue, (2004-2018) 1339.5 Infectious Immunology Distribution Share (2010-2011) 1419.6 Infectious Immunology, United Kingdom, Company Share (2010-2011) 14210 Microbiology Culture In United Kingdom 14410.1 Microbiology Culture, Market Segmentation 14410.2 Microbiology Culture Market, United Kingdom, Revenue Mix ($m), 2011 14510.3 Microbiology Culture Market, United Kingdom, Segment Contribution (%), 2011 14610.4 Microbiology Culture Overall Revenue, (2004-2018) 14710.5 Microbiology Culture Distribution Share (2010-2011) 15510.6 Microbiology Culture, United Kingdom, Company Share (2010-2011) 156
    • 11 Overview of Key Companies in United Kingdom In Vitro Diagnostics Market 15811.1 Siemens Healthcare 15811.2 F. Hoffmann-La Roche Ltd. 15911.3 Abbott Laboratories 16011.4 Beckman Coulter, Inc. 16111.5 Sysmex Corporation 16211.6 bioMerieux S.A. 16311.7 Ortho-Clinical Diagnostics Inc. 16411.8 Bio-Rad Laboratories, Inc. 16411.9 Becton, Dickinson and Company 16411.10 Alere Inc. 16511.11 Phadia AB 16511.12 Mindray Medical International Limited 16511.13 Qiagen N.V. 16611.14 DiaSorin S.p.A 16611.15 ELITech Group 16711.16 PerkinElmer, Inc. 16711.17 Thermo Fisher Scientific Inc. 16811.18 Atlas Medical 16811.19 Gen-Probe Incorporated 16811.20 Horiba, Ltd. 16911.21 Diagnostica Stago, Inc. 16911.22 Life Technologies Corporation 16911.23 Hologic, Inc. 17012 In Vitro Diagnostics Market Pipeline Products 17112.1 Clinical Chemisty Market Pipeline Products 17112.2 Immuno Chemistry Market Pipeline Products 17512.3 Haematology Market Pipeline Products 18612.4 Infectious Immunology Market Pipeline Products 18812.5 Microbiology Culture Market Pipeline Products 19512.6 Histology And Cytology Market Pipeline Products 19612.7 Genetic Testing Market Pipeline Products 19713 Financial Deals Landscape 20213.1 Acquisition 20213.2 Partnerships 20814 Recent Developments 26814.1 Strategy And Business Planning 26814.2 Government and Public Interest 27514.3 Product News 28215 Appendix 29015.1 Definitions of Markets Covered in the Report 29115.2 Research Methodology 302
    • 15.3 Secondary Research 30215.4 Primary Research 30215.5 Models 30315.6 Forecasts 30315.7 Expert Panels 30315.8 GlobalData Consulting 30415.9 Currency Conversion 30415.10 Contact Us 30415.11 Disclaimer 3041.1 List of TablesTable 1: In Vitro Diagnostics, United Kingdom, Overall Revenue ($m), USD Constant, 2004-201823Table 2: In Vitro Diagnostics Market, United Kingdom, Category Contribution (%), 2011 25Table 3: In Vitro Diagnostics Market, United Kingdom, Cross-Category Analysis, 2004-2018 27Table 4: In Vitro Diagnostics, United Kingdom, Overall Revenue ($m), USD Constant, Historic,2004-2011 29Table 5: In Vitro Diagnostics, United Kingdom, Overall Revenue ($m), USD Constant, Forecast,2011-2018 31Table 6: In Vitro Diagnostics, United Kingdom, Company Share by Revenue ($m), USD Constant,2010-2011 33Table 7: Clinical Chemistry Market, United Kingdom, Segment Contribution (%), 2011 36Table 8: Clinical Chemistry, United Kingdom, Revenue ($m) USD Constant, by Segment, Historic,2004-2011 38Table 9: Clinical Chemistry, United Kingdom, Revenue ($m) USD Constant, by Segment,Forecast, 2011-2018 40Table 10: Clinical Chemisty Analyzers, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 42Table 11: Clinical Chemisty Analyzers, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 44Table 12: Urine Analysis, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment,Historic, 2004-2011 46Table 13: Urine Analysis, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment,Forecast, 2011-2018 48Table 14: Clinical Chemistry, United Kingdom, Distribution Share by Revenue ($m), USDConstant, 2010-2011 49Table 15: Clinical Chemistry, United Kingdom, Company Share by Revenue ($m), USD Constant,2010-2011 51Table 16: Genetic Testing Market, United Kingdom, Segment Contribution (%), 2011 54Table 17: Genetic Testing, United Kingdom, Revenue ($m) USD Constant, by Segment, Historic,2004-2011 56Table 18: Genetic Testing, United Kingdom, Revenue ($m) USD Constant, by Segment, Forecast,
    • 2011-2018 58Table 19: Genetic Testing, United Kingdom, Distribution Share by Revenue ($m), USD Constant,2010-2011 59Table 20: Genetic Testing, United Kingdom, Company Share by Revenue ($m), USD Constant,2010-2011 61Table 21: Haematology Market, United Kingdom, Segment Contribution (%), 2011 64Table 22: Haematology, United Kingdom, Revenue ($m) USD Constant, by Segment, Historic,2004-2011 66Table 23: Haematology, United Kingdom, Revenue ($m) USD Constant, by Segment, Forecast,2011-2018 68Table 24: Haematology Reagents, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 70Table 25: Haematology Reagents, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 72Table 26: Immunohaematology, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment,Historic, 2004-2011 74Table 27: Immunohaematology, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment,Forecast, 2011-2018 76Table 28: Haemostasis, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment,Historic, 2004-2011 78Table 29: Haemostasis, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment,Forecast, 2011-2018 80Table 30: Haematology Rapid Tests, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 82Table 31: Haematology Rapid Tests, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 84Table 32: Haematology Cell Counters, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 86Table 33: Haematology Cell Counters, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 88Table 34: Haematology, United Kingdom, Distribution Share by Revenue ($m), USD Constant,2010-2011 89Table 35: Haematology, United Kingdom, Company Share by Revenue ($m), USD Constant,2010-2011 91Table 36: Histology And Cytology Market, United Kingdom, Segment Contribution (%), 2011 94Table 37: Histology And Cytology, United Kingdom, Revenue ($m) USD Constant, by Segment,Historic, 2004-2011 96Table 38: Histology And Cytology, United Kingdom, Revenue ($m) USD Constant, by Segment,Forecast, 2011-2018 98Table 39: Histology And Cytology, United Kingdom, Distribution Share by Revenue ($m), USDConstant, 2010-2011 99Table 40: Histology And Cytology, United Kingdom, Company Share by Revenue ($m), USD
    • Constant, 2010-2011 101Table 41: Immuno Chemistry Market, United Kingdom, Segment Contribution (%), 2011 103Table 42: Immuno Chemistry, United Kingdom, Revenue ($m) USD Constant, by Segment,Historic, 2004-2011 105Table 43: Immuno Chemistry, United Kingdom, Revenue ($m) USD Constant, by Segment,Forecast, 2011-2018 107Table 44: Disease Specific Immunochemistry, United Kingdom, Revenue ($m) USD Constant, bySub-Segment, Historic, 2004-2011 109Table 45: Disease Specific Immunochemistry, United Kingdom, Revenue ($m) USD Constant, bySub-Segment, Forecast, 2011-2018 111Table 46: Drugs of Abuse / Toxicology, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 113Table 47: Drugs of Abuse / Toxicology, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 115Table 48: Endocrinology Tests, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment,Historic, 2004-2011 117Table 49: Endocrinology Tests, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment,Forecast, 2011-2018 119Table 50: Immunochemistry Rapid Tests, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 121Table 51: Immunochemistry Rapid Tests, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 123Table 52: Therapeutic Drug Monitoring, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 125Table 53: Therapeutic Drug Monitoring, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 127Table 54: Immunochemistry Analyzers, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 129Table 55: Immunochemistry Analyzers, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 131Table 56: Immuno Chemistry, United Kingdom, Distribution Share by Revenue ($m), USDConstant, 2010-2011 132Table 57: Immuno Chemistry, United Kingdom, Company Share by Revenue ($m), USD Constant,2010-2011 134Table 58: Infectious Immunology Market, United Kingdom, Segment Contribution (%), 2011 137Table 59: Infectious Immunology, United Kingdom, Revenue ($m) USD Constant, by Segment,Historic, 2004-2011 139Table 60: Infectious Immunology, United Kingdom, Revenue ($m) USD Constant, by Segment,Forecast, 2011-2018 141Table 61: Infectious Immunology Rapid Tests, United Kingdom, Revenue ($m) USD Constant, bySub-Segment, Historic, 2004-2011 143Table 62: Infectious Immunology Rapid Tests, United Kingdom, Revenue ($m) USD Constant, by
    • Sub-Segment, Forecast, 2011-2018 145Table 63: Infectious Immunology, United Kingdom, Distribution Share by Revenue ($m), USDConstant, 2010-2011 146Table 64: Infectious Immunology, United Kingdom, Company Share by Revenue ($m), USDConstant, 2010-2011 148Table 65: Microbiology Culture Market, United Kingdom, Segment Contribution (%), 2011 151Table 66: Microbiology Culture, United Kingdom, Revenue ($m) USD Constant, by Segment,Historic, 2004-2011 153Table 67: Microbiology Culture, United Kingdom, Revenue ($m) USD Constant, by Segment,Forecast, 2011-2018 155Table 68: Microbiology Analyzers, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 157Table 69: Microbiology Analyzers, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 159Table 70: Microbiology Culture, United Kingdom, Distribution Share by Revenue ($m), USDConstant, 2010-2011 160Table 71: Microbiology Culture, United Kingdom, Company Share by Revenue ($m), USDConstant, 2010-2011 162Table 72: Clinical Chemisty Market Pipeline Products 176Table 73: Immuno Chemistry Market Pipeline Products 180Table 74: Haematology Market Pipeline Products 191Table 75: Infectious Immunology Market Pipeline Products 193Table 76: Microbiology Culture Market Pipeline Products 200Table 77: Histology And Cytology Market Pipeline Products 201Table 78: Genetic Testing Market Pipeline Products 202Table 79: Illumina Acquires BlueGnome, Provider Of Cytogenetics And In Vitro FertilizationScreening Solutions 207Table 80: Becton, Dickinson Acquires Sirigen, Developer Of Polymer Dyes 208Table 81: Abingdon Health Acquires 80% Stake In Forsite Diagnostics 210Table 82: Abingdon Health To Acquire 50.1% Stake In Molecular Vision From Imperial InnovationsGroup 211Table 83: Quintiles Acquires Minority Stake In Oxford Cancer Biomarkers For $5 Million 212Table 84: bioMerieux Enters Into Licensing Agreement With Quanterix For Simoa Technology 213Table 85: Crown Bioscience Enters Into Co-Development Agreement With Horizon Discovery 214Table 86: Affinity Biosensors Enters Into Distribution Agreement With Malvern Instruments ForArchimedes Particle Metrology System 215Table 87: Agenix Enters Into Licensing Agreement With Tyrian Diagnostics For DiagnostIQ 216Table 88: BioDot Enters Into Co-Marketing Agreement With JOT Automation 217Table 89: AbD Serotec Enters Into Licensing Agreement With DiaSorin For HuCAL Antibodies 218Table 90: BD Diagnostic Systems Enters Into Agreement With Lab21 To Develop New OncologyAssays 219Table 91: CellaVision Enters Into Distribution Agreement With Siemens Healthcare For Digital
    • Microscopy Hematology Solutions 220Table 92: Med BioGene Amends Licensing Agreement With Precision Therapeutics ForLungExpress Dx Test 221Table 93: Ovizio Imaging Systems Enters Into Distribution Agreement With ApplikonBiotechnology 222Table 94: Life Technologies Enters Into Co-Marketing Agreement With Pathogenica 223Table 95: CML HealthCare Enters Into Agreement With MaRS Innovation 224Table 96: Akrivis Technologies Enters Into Co-Development Agreement With United StatesBiological 225Table 97: Castle Biosciences Enters Into Licensing Agreement With Brigham and WomensHospital For Mesothelioma Test 226Table 98: Scienion Enters Into Co-Marketing Agreement With Maine Manufacturing For ProteinArray Products 227Table 99: GeneCentric Diagnostics Enters Into Licensing Agreement With University of NorthCarolina 228Table 100: Dolomite Centre Enters Into Licensing Agreement With Japan Science and TechnologyAgency For Microdroplet Generation Technology 229Table 101: Epistem Enters Into Distribution Agreement With Becton Dickinson For MycobacteriumTB Test 230Table 102: Waters Enters Into Co-Development Agreement With Nonlinear Dynamics 231Table 103: EKF Diagnostics Enters Into Licensing Agreement With Joslin Diabetes Center 232Table 104: SciFluor Life Sciences Enters Into Distribution Agreement With Sigma-Aldrich ForPhenoFluor 233Table 105: Immuno-Biological Labs Enters Into Licensing Agreement With IBL International 234Table 106: MDxHealth Enters Into Licensing Agreement With Merck For MGMT Diagnostic Test235Table 107: Lab21 Enters Into Co-Development Agreement With Pharma Company 236Table 108: NicOx Enters Into Licensing Agreement With Rapid Pathogen Screening ForAdenoPlus 237Table 109: Immunexpress Enters Into Licensing Agreement With Debiopharm And Biocartis 238Table 110: Omega Diagnostics Enters Into Licensing Agreement With Burnet Institute For CD4POC Test 239Table 111: KineMed Enters Into Co-Development Agreement With GlaxoSmithKline 240Table 112: One Lambda Enters Into Co-Marketing Agreement With CellTrend 241Table 113: GE Healthcare Enters Into Co-Development Agreement With Commonwealth Scientificand Industrial Research 242Table 114: Clarient Diagnostic Services Enters Into Licensing Agreement With Insight GeneticsFor ALK Cancer Biomarker 243Table 115: Affymetrix Enters Into Technology Integration Agreement With Leica Microsystems 244Table 116: Biocartis Enters Into Co-Development Agreement With Wellcome Trust SangerInstitute And Philips Research Europe For Oncology Diagnostics 245Table 117: Ventana Medical Enters Into Licensing Agreement With Gen-Probe For IP Of ERG
    • Marker 246Table 118: Affymetrix Enters Into Distribution Agreement With ScreenCell For Circulating TumorCell Technology 247Table 119: Hycor Biomedical Enters Into Distribution Agreement With Roche For KOVA 248Table 120: Opko Health Enters Into Licensing Agreement With International Health TechnologyFor Prostate Cancer Biomarker Panel 249Table 121: Dolomite Centre Enters Into Co-Development Agreement With LioniX 250Table 122: Genome Diagnostics Enters Into Co-Marketing Agreement With Qiagen ForLongRange PCR Kit 251Table 123: Biofortuna Extends Co-Marketing Agreement With Abbott Labs For SSPGo 252Table 124: Novo Nordisk Enters Into Co-Development Agreement With Oxford University 253Table 125: Pressure BioSciences Enters Into Licensing Agreement With Target Discovery ForPressure Cycling Technology 254Table 126: LipoScience Enters Into Licensing Agreement With Cleveland Clinic 255Table 127: GE Healthcare Enters Into Co-Development Agreement With NXT2B For CompactCyclotron And PET Tracer System 256Table 128: NexDx Enters Into Licensing Agreement With University of California For EpigeneticBiomarkers 257Table 129: LAB21 Enters Into Co-Development Agreement With IVD Company For AspergillusMolecular Assay 258Table 130: Randox Labs Enters Into Licensing Agreement With Proteome Sciences For StrokeBiomarker 259Table 131: Bio-Rad Labs Extends Distribution Agreement With Luminex For MAGPIX 260Table 132: A*STAR Enters Into Co-Development Agreement With QuantuMDx Group 261Table 133: DiaGenic Enters Into Co-Development Agreement With GE Healthcare 262Table 134: DNA Electronics Enters Into Licensing Agreement With Gene Onyx For GenalysisTechnology 263Table 135: Epistem Holdings Enters Into Co-Development Agreement With GlaxoSmithKline 264Table 136: ANGLE Enters Into Co-Development Agreement With Paterson Institute for CancerResearch 265Table 137: Yissum Research Development Company Enters Into Licensing Agreement WithBioConnections For Commercialization Of Kits 266Table 138: Oxford Gene Technology Enters Into Licensing Agreement With Oslo UniversityHospital And University of Oslo 267Table 139: VolitionRx And Abcodia Partner To Advance Discovery Of Blood Based BiomarkersFor Cancer 268Table 140: Horizon Diagnostics Enters Into Licensing Agreement With UK NEQAS 269Table 141: Thermo Fisher Scientific Enters Into Distribution Agreement With Abbott For PCTAssay For Sepsis 270Table 142: Abbott Labs Expands Its Co-Development Agreement With GlaxoSmithKlineBiologicals 271Table 143: Dolomite Enters Into Co-Development Agreement With Clearbridge BioMedics 272
    • 1.2 List of FiguresFigure 1: In Vitro Diagnostics, Market Segmentation 21Figure 2: In Vitro Diagnostics, United Kingdom, Overall Revenue ($m), USD Constant, 2004-201822Figure 3: In Vitro Diagnostics Market, United Kingdom, Revenue Mix ($m), 2011 24Figure 4: In Vitro Diagnostics Market, United Kingdom, Category Contribution (%), 2011 25Figure 5: In Vitro Diagnostics Market, United Kingdom, Cross-Category Analysis, 2004-2018 26Figure 6: In Vitro Diagnostics, United Kingdom, Overall Revenue ($m), USD Constant, Historic,2004-2011 28Figure 7: In Vitro Diagnostics, United Kingdom, Overall Revenue ($m), USD Constant, Forecast,2011-2018 30Figure 8: In Vitro Diagnostics, United Kingdom, Company Share (%), 2011 32Figure 9: Clinical Chemistry, Market Segmentation 34Figure 10: Clinical Chemistry Market, United Kingdom, Revenue Mix ($m), 2011 35Figure 11: Clinical Chemistry Market, United Kingdom, Segment Contribution (%), 2011 36Figure 12: Clinical Chemistry, United Kingdom, Revenue ($m) USD Constant, by Segment,Historic, 2004-2011 37Figure 13: Clinical Chemistry, United Kingdom, Revenue ($m) USD Constant, by Segment,Forecast, 2011-2018 39Figure 14: Clinical Chemisty Analyzers, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 41Figure 15: Clinical Chemisty Analyzers, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 43Figure 16: Urine Analysis, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment,Historic, 2004-2011 45Figure 17: Urine Analysis, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment,Forecast, 2011-2018 47Figure 18: Clinical Chemistry, United Kingdom, Company Share (%), 2011 50Figure 19: Genetic Testing, Market Segmentation 52Figure 20: Genetic Testing Market, United Kingdom, Revenue Mix ($m), 2011 53Figure 21: Genetic Testing Market, United Kingdom, Segment Contribution (%), 2011 54Figure 22: Genetic Testing, United Kingdom, Revenue ($m) USD Constant, by Segment, Historic,2004-2011 55Figure 23: Genetic Testing, United Kingdom, Revenue ($m) USD Constant, by Segment,Forecast, 2011-2018 57Figure 24: Genetic Testing, United Kingdom, Company Share (%), 2011 60Figure 25: Haematology Market, Market Segmentation 62Figure 26: Haematology Market, United Kingdom, Revenue Mix ($m), 2011 63Figure 27: Haematology Market, United Kingdom, Segment Contribution (%), 2011 64Figure 28: Haematology, United Kingdom, Revenue ($m) USD Constant, by Segment, Historic,2004-2011 65
    • Figure 29: Haematology, United Kingdom, Revenue ($m) USD Constant, by Segment, Forecast,2011-2018 67Figure 30: Haematology Reagents, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 69Figure 31: Haematology Reagents, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 71Figure 32: Immunohaematology, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 73Figure 33: Immunohaematology, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 75Figure 34: Haemostasis, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment,Historic, 2004-2011 77Figure 35: Haemostasis, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment,Forecast, 2011-2018 79Figure 36: Haematology Rapid Tests, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 81Figure 37: Haematology Rapid Tests, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 83Figure 38: Haematology Cell Counters, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 85Figure 39: Haematology Cell Counters, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 87Figure 40: Haematology, United Kingdom, Company Share (%), 2011 90Figure 41: Histology and Cytology Market, Market Segmentation 92Figure 42: Histology And Cytology Market, United Kingdom, Revenue Mix ($m), 2011 93Figure 43: Histology And Cytology Market, United Kingdom, Segment Contribution (%), 2011 94Figure 44: Histology And Cytology, United Kingdom, Revenue ($m) USD Constant, by Segment,Historic, 2004-2011 95Figure 45: Histology And Cytology, United Kingdom, Revenue ($m) USD Constant, by Segment,Forecast, 2011-2018 97Figure 46: Histology And Cytology, United Kingdom, Company Share (%), 2011 100Figure 47: Immuno Chemistry Market, United Kingdom, Revenue Mix ($m), 2011 102Figure 48: Immuno Chemistry Market, United Kingdom, Segment Contribution (%), 2011 103Figure 49: Immuno Chemistry, United Kingdom, Revenue ($m) USD Constant, by Segment,Historic, 2004-2011 104Figure 50: Immuno Chemistry, United Kingdom, Revenue ($m) USD Constant, by Segment,Forecast, 2011-2018 106Figure 51: Disease Specific Immunochemistry, United Kingdom, Revenue ($m) USD Constant, bySub-Segment, Historic, 2004-2011 108Figure 52: Disease Specific Immunochemistry, United Kingdom, Revenue ($m) USD Constant, bySub-Segment, Forecast, 2011-2018 110Figure 53: Drugs of Abuse / Toxicology, United Kingdom, Revenue ($m) USD Constant, by Sub-
    • Segment, Historic, 2004-2011 112Figure 54: Drugs of Abuse / Toxicology, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 114Figure 55: Endocrinology Tests, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment,Historic, 2004-2011 116Figure 56: Endocrinology Tests, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment,Forecast, 2011-2018 118Figure 57: Immunochemistry Rapid Tests, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 120Figure 58: Immunochemistry Rapid Tests, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 122Figure 59: Therapeutic Drug Monitoring, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 124Figure 60: Therapeutic Drug Monitoring, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 126Figure 61: Immunochemistry Analyzers, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 128Figure 62: Immunochemistry Analyzers, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment, Forecast, 2011-2018 130Figure 63: Immuno Chemistry, United Kingdom, Company Share (%), 2011 133Figure 64: Infectious Immunology, Market Segmentation 135Figure 65: Infectious Immunology Market, United Kingdom, Revenue Mix ($m), 2011 136Figure 66: Infectious Immunology Market, United Kingdom, Segment Contribution (%), 2011 137Figure 67: Infectious Immunology, United Kingdom, Revenue ($m) USD Constant, by Segment,Historic, 2004-2011 138Figure 68: Infectious Immunology, United Kingdom, Revenue ($m) USD Constant, by Segment,Forecast, 2011-2018 140Figure 69: Infectious Immunology Rapid Tests, United Kingdom, Revenue ($m) USD Constant, bySub-Segment, Historic, 2004-2011 142Figure 70: Infectious Immunology Rapid Tests, United Kingdom, Revenue ($m) USD Constant, bySub-Segment, Forecast, 2011-2018 144Figure 71: Infectious Immunology, United Kingdom, Company Share (%), 2011 147Figure 72: Microbiology Culture, Market Segmentation 149Figure 73: Microbiology Culture Market, United Kingdom, Revenue Mix ($m), 2011 150Figure 74: Microbiology Culture Market, United Kingdom, Segment Contribution (%), 2011 151Figure 75: Microbiology Culture, United Kingdom, Revenue ($m) USD Constant, by Segment,Historic, 2004-2011 152Figure 76: Microbiology Culture, United Kingdom, Revenue ($m) USD Constant, by Segment,Forecast, 2011-2018 154Figure 77: Microbiology Analyzers, United Kingdom, Revenue ($m) USD Constant, by Sub-Segment, Historic, 2004-2011 156Figure 78: Microbiology Analyzers, United Kingdom, Revenue ($m) USD Constant, by Sub-
    • Segment, Forecast, 2011-2018 158Figure 79: Microbiology Culture, United Kingdom, Company Share (%), 2011 161Figure 80: Siemens Healthcare, Company Share (%),United Kingdom In Vitro Diagnostics Market,2011 163Figure 81: F. Hoffmann-La Roche Ltd., Company Share (%),United Kingdom In Vitro DiagnosticsMarket, 2011 164Figure 82: Abbott Laboratories, Company Share (%),United Kingdom In Vitro Diagnostics Market,2011 165Figure 83: Beckman Coulter, Inc., Company Share (%),United Kingdom In Vitro DiagnosticsMarket, 2011 166Figure 84: Sysmex Corporation, Company Share (%),United Kingdom In Vitro Diagnostics Market,2011 167Figure 85: bioMerieux S.A., Company Share (%),United Kingdom In Vitro Diagnostics Market,2011 168Contact: sales@reportsandreports.com for more information.